soul trial oral semaglutide cardiovascular outcomes 2025 Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the Randomized Pharmacy - At ADA 2025,

So in March, the FDA actually approved a new indication for a WeGovy, or semaglutide, to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease, who are either obese or overweight

Volkert D, et al

Other side effects included vomiting, diarrhea and stomach pain, but only five to 10 percent of people experienced these

[DOI] [PubMed] [Google Scholar] 58.Peng MG, Gokoffski KK

GLP-1 activation makes you eat less and feel satisfied sooner

Naltrexone specifically is used in addiction medicine because it blocks opioid receptors, which also plays a role in food reward pathways